Abstract:Abstract Inflammatory processes involving altered microglial activity may play a relevant role in the pathophysiology of depressive disorders. Glial fibrillary acidic protein (GFAP) and calcium-binding protein S100B are considered microglial markers. To date, their role has been studied in the serum and tissue material of patients with unipolar depression but not in the cerebrospinal fluid (CSF). Therefore, the aim of the current study was to examine GFAP and S100B levels in the CSF of patients with major depression to better understand their role in affective disorders. In this retrospective study, 102 patients with unipolar depression and 39 mentally healthy controls with idiopathic intracranial hypertension were investigated. GFAP and S100B levels were measured using commercially available ELISA kits. CSF routine parameters were collected during routine clinical care. The mean values of GFAP and S100B were compared using age (and sex) corrected ANOVAs. Matched subgroups were analyzed by using an independent sample t -test. In addition, correlation analyses between GFAP/S100B levels and CSF routine parameters were performed within the patient group. Patients with unipolar depression had significantly higher levels of GFAP than controls (733.22 pg/ml vs. 245.56 pg/ml, p < 0.001). These results remained significant in a sub-analysis in which all controls were compared with patients suffering from depression matched 1:1 by age and sex (632.26 pg/ml vs. 245.56 pg/ml, p < 0.001). Levels of S100B did not differ significantly between patients and controls (1.06 ng/ml vs. 1.17 ng/ml, p = 0.385). GFAP levels correlated positively with albumin quotients ( p < 0.050), S100B levels correlated positively with white blood cell counts ( p = 0.001), total protein concentrations ( p < 0.001), and albumin quotients ( p = 0.001) in the CSF. The significance of the study is limited by its retrospective and open design, methodological aspects, and the control group with idiopathic intracranial hypertension. In conclusion, higher GFAP levels in patients with depression may be indicative of altered microglia activity, especially in astrocytes, in patients with unipolar depression. In addition, correlation analyses support the idea that S100B levels could be related to the integrity of the blood–brain/CSF barrier. Further multimodal and longitudinal studies are necessary to validate these findings and clarify the underlying biological processes.

Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: A systematic review and meta-analysis

Plasma glial fibrillary acidic protein and neurofilament light chain in behavioural variant frontotemporal dementia and primary psychiatric disorders

Neurofilament light chain plasma levels in major depressive disorder: a brief research report

Neurofilament light chain as a promising biomarker for depression diagnosis: a systematic review and meta-analysis

Plasma Glial Fibrillary Acidic Protein and Neurofilament Light are Elevated in Bipolar Disorder: Evidence for Neuroprogression and Astrocytic Activation

Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls

Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson’s disease

Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression

Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting

Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases

Neurofilaments as biomarkers in neurological disorders

Neurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates

An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease

A multicentre validation study of the diagnostic value of plasma neurofilament light

Neurofilament light chain as a biomarker in neurological disorders

Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Elevated plasma neurofilament light and glial fibrillary acidic protein in epilepsy versus nonepileptic seizures and nonepileptic disorders

Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression

Evaluation of Cerebrospinal Fluid Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic